Literature DB >> 27355571

p21 governs p53's repressive side.

Martin Fischer1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27355571      PMCID： PMC5105911          DOI： 10.1080/15384101.2016.1205393

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  7 in total

Review 1.  MicroRNAs in the p53 network: micromanagement of tumour suppression.

Authors:  Heiko Hermeking
Journal:  Nat Rev Cancer       Date:  2012-08-17       Impact factor: 60.716

Review 2.  Expanding the p53 regulatory network: LncRNAs take up the challenge.

Authors:  Elena Grossi; Yolanda Sánchez; Maite Huarte
Journal:  Biochim Biophys Acta       Date:  2015-07-18

Review 3.  The first 30 years of p53: growing ever more complex.

Authors:  Arnold J Levine; Moshe Oren
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

4.  The transcription factor p53: not a repressor, solely an activator.

Authors:  Martin Fischer; Lydia Steiner; Kurt Engeland
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

5.  The p53-p21-DREAM-CDE/CHR pathway regulates G2/M cell cycle genes.

Authors:  Martin Fischer; Marianne Quaas; Lydia Steiner; Kurt Engeland
Journal:  Nucleic Acids Res       Date:  2015-09-17       Impact factor: 16.971

6.  Integration of TP53, DREAM, MMB-FOXM1 and RB-E2F target gene analyses identifies cell cycle gene regulatory networks.

Authors:  Martin Fischer; Patrick Grossmann; Megha Padi; James A DeCaprio
Journal:  Nucleic Acids Res       Date:  2016-06-08       Impact factor: 16.971

7.  Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex.

Authors:  Martin Fischer; Marianne Quaas; Annina Nickel; Kurt Engeland
Journal:  Oncotarget       Date:  2015-12-08
  7 in total
  9 in total

1.  Simvastatin Inhibits Cell Proliferation and Migration in Human Anaplastic Thyroid Cancer.

Authors:  Mei-Chieh Chen; Yuan-Chin Tsai; Jen-Ho Tseng; Jr-Jiun Liou; Steve Horng; Heng-Ching Wen; Yu-Ching Fan; Wen-Bin Zhong; Sung-Po Hsu
Journal:  Int J Mol Sci       Date:  2017-12-13       Impact factor: 5.923

2.  Human papilloma virus E7 oncoprotein abrogates the p53-p21-DREAM pathway.

Authors:  Martin Fischer; Sigrid Uxa; Clara Stanko; Thomas M Magin; Kurt Engeland
Journal:  Sci Rep       Date:  2017-06-01       Impact factor: 4.379

3.  SOG1 activator and MYB3R repressors regulate a complex DNA damage network in Arabidopsis.

Authors:  Clara Bourbousse; Neeraja Vegesna; Julie A Law
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-12       Impact factor: 11.205

4.  Transcriptional mutagenesis dramatically alters genome-wide p53 transactivation landscape.

Authors:  Shuo Liang; Monika Ezerskyte; Jingwen Wang; Vicent Pelechano; Kristian Dreij
Journal:  Sci Rep       Date:  2020-08-11       Impact factor: 4.379

5.  Puf-A promotes cancer progression by interacting with nucleophosmin in nucleolus.

Authors:  Huan-Chieh Cho; Yenlin Huang; Jung-Tung Hung; Tsai-Hsien Hung; Kai-Chun Cheng; Yun-Hen Liu; Ming-Wei Kuo; Sheng-Hung Wang; Alice L Yu; John Yu
Journal:  Oncogene       Date:  2022-01-09       Impact factor: 9.867

6.  TargetGeneReg 2.0: a comprehensive web-atlas for p53, p63, and cell cycle-dependent gene regulation.

Authors:  Martin Fischer; Robert Schwarz; Konstantin Riege; James A DeCaprio; Steve Hoffmann
Journal:  NAR Cancer       Date:  2022-03-23

Review 7.  Census and evaluation of p53 target genes.

Authors:  M Fischer
Journal:  Oncogene       Date:  2017-03-13       Impact factor: 9.867

Review 8.  High-Risk Human Papillomaviral Oncogenes E6 and E7 Target Key Cellular Pathways to Achieve Oncogenesis.

Authors:  Nicole S L Yeo-Teh; Yoshiaki Ito; Sudhakar Jha
Journal:  Int J Mol Sci       Date:  2018-06-08       Impact factor: 5.923

Review 9.  Common Functions of Disordered Proteins across Evolutionary Distant Organisms.

Authors:  Arndt Wallmann; Christopher Kesten
Journal:  Int J Mol Sci       Date:  2020-03-19       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.